| Entry |
|
|---|
| Name |
Zilucoplan (USAN/INN) |
|---|
| Formula |
C172H278N24O55
|
|---|
| Exact mass |
3559.9694
|
|---|
| Mol weight |
3562.17
|
|---|
| Class |
Metabolizing enzyme substrate
DG02980 CYP4F2 substrate
|
|---|
| Remark |
| Product (DG03224): | D12356<JP/US> |
|
|---|
| Efficacy |
Autoimmune disease treatment, Complement C5 inhibitor |
|---|
| Comment |
Treatment of paroxysmal nocturnal hemoglobinuria
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04610 | Complement and coagulation cascades |
| hsa04613 | Neutrophil extracellular trap formation |
|
|---|
| Metabolism |
Enzyme: CYP4F2 [HSA: 8529]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AJ Complement inhibitors
L04AJ06 Zilucoplan
D12357 Zilucoplan (USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02980 CYP4F2 substrate
DG03224 Zilucoplan
D12357 Zilucoplan
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Peptidase inhibitors
alpha2M family
C5
D12357 Zilucoplan (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12357
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02980 CYP4F2 substrate
DG03224 Zilucoplan
|
|---|
| Other DBs |
|
|---|